New blood-based test detects lymph node metastasis in individuals with high-risk T1 colorectal cancer
Scientists at City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, have developed a novel, noninvasive liquid biopsy test for detecting lymph node metastasis in individuals with high-risk T1 colorectal carcinoma. Research on the development of the blood test was reported in a new study published in
Gastroenterology, a journal of the American Gastroenterological Association.
This blood-based test is an example of the theranostic (a term that combines therapeutic and diagnostic ) approach at City of Hope, whose goal is to help every patient receive personalized treatment appropriate for their specific disease. Development of blood-based biopsies to detect and monitor tumors is one of the leading-edge technologies under investigation to help patients with cancer.
Share this article
Share this article
The collaboration is a 3-year joint effort by Prenetics R&D Team, Oxford University and Oxford Suzhou for Advanced Research (OSCAR) for Molecular Diagnostics
A new Prenetics Innovation Technology Centre is established for advanced molecular diagnostics
Collaboration follows successful acquisition and commercialization of Oxsed, an Oxford University Spin-out, to scale rapid Covid-19 test globally
HONG KONG, April 19, 2021 /PRNewswire/ Prenetics Limited, a global leader in diagnostics and genetic testing, Oxford University and Oxford Suzhou Centre for Advanced Research (OSCAR) have signed multi-million dollar collaboration agreements to further develop the award-winning OxLAMP™ technology, a rapid, molecular testing technology for infectious diseases.
QIAGEN N.V. to Report First Quarter 2021 Results
22:05 Central European Time
(CET)
(EDT)
15:00 CET
Conference call and webcast details Interested parties may listen to the call by dialling:
+1 929 477 0402 (U.S.), +44 (0)330 336 9125 (UK), +49 (0) 69 2222 25574 (Germany).
To avoid waiting time, please join the event conference
5-10 minutes prior to the start time.
Conference ID: 8750862
https://globalmeet.webcasts.com/viewer/event.jsp?ei=1447003&tp key=fa89ebc26d
A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/viewer/event.jsp?ei=1447003&tp key=fa89ebc26d
Contact: IR@qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and ot
Share this article
Share this article
ABBOTT PARK, Ill., April 20, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2021.
First-quarter sales of $10.5 billion increased 35.3 percent on a reported basis and 32.9 percent on an organic basis, which excludes the impact of foreign exchange.
First-quarter GAAP diluted EPS was $1.00 and adjusted diluted EPS, which excludes specified items, was $1.32, reflecting 103.1 percent growth versus the prior year.
1
Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of at least $3.74. Projected full-year adjusted diluted EPS from continuing operations of at least $5.00 remains unchanged and reflects growth of more than 35 percent versus the prior year.